Neutralization of local toxicity induced by Vipera russelli phospholipase A2 by lipophilic derivative of ascorbic acid

Current Topics in Medicinal Chemistry

Volumn 11, Issue 20, 2011, Pages 2531-2539

  Mohamed, Riyaz ^a   Shivaprasad, Holenarasipura V ^b   Jameel, Noor M ^c   Shekar, Mysore A ^c,d   Vishwanath, Bannikuppe S ^a  

^a UNIVERSITY OF MYSORE   (India)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Apoorva Diabetes Foundation Centre for Diabetes Care and Research   (India)

^d MYSORE MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

Ascorbic acid 6 palmitate; Lung haemorrhage; Myotoxicity; Vipera russelli

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3,N DIMETHYL N [1 METHYL 3 (4 METHYL 1 PIPERIDINYL)PROPYL]BENZENESULFONAMIDE; ASCORBIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 8A; CALCIUM; CREATINE KINASE; L ASCORBIC ACID 6 PALMITATE; LACTATE DEHYDROGENASE; PHOSPHOLIPASE A2; SB 691673; SNAKE VENOM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG HEMORRHAGE; MOLECULAR DOCKING; MOUSE; NONHUMAN; SNAKE;

EID: 80054069737     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611797633429     Document Type: Article

References (46)

1. Gutiérrez, J.M.; Lomonte, B.; León, G.; Rucavado, A.; Chaves, F.; Angulo, Y. Trends in snakebite. 2007, 13(28), 2935-50.
2. Gutiérrez, J.M.; Theakston, R.D.; Warrell, D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med., 2006, 3(6), e150.
3. Gutiérrez, J.M.; León, G.; Rojas, G.; Lomonte, B.; Rucavado, A; Chaves, F. Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom. Toxicon, 1998, 36(11), 1529-38.
4. Soares, A.M.; Ticli, F.K.; Marcussi, S. Medicinal plants with inhibitory properties against snake venoms. Curr. Med. Chem., 2005, 12, 2625-2641.
5. B.; León, G.; Angulo, Y.; Rucavado, A.; Núñez, V. Neutralization of Bothrops asper venom by antibodies, natural products and synthetic drugs: contributions to understanding snakebite envenomings and their treatment. Toxicon, 2009, 54(7), 1012-28.
6. Angulo, Y.; Lomonte, B. Biochemistry and toxicology of toxins purified from the venom of the snake Bothrops Asper. Toxicon, 2009, 54(7), 949-957.
7. Lomonte, B.; León, G.; Angulo, Y.; Rucavado, A.; Núñez, V. Neutralization of Bothrops asper venom by antibodies, natural products and synthetic drugs: contributions to understanding snakebite envenomings and their treatment. Toxicon, 2009, 54(7), 1012-1028.
8. 2 enzymes. Toxicon, 2003, 42(8), 827-840.
9. Mukherjee, A.K. Correlation between the phospholipids domains of the target cell membrane and the extent of Naja kaouthia PLA(2)-induced membrane damage: evidence of distinct catalytic and cytotoxic sites in PLA(2) molecules. Biochim. Biophys. Acta, 2007, 1770(2), 187-195.
10. Otero, R.; Gutiérrez, J.; Beatriz Mesa, M.; Duque, E.; Rodríguez, O.; Luis Arango, J.; Gómez, F.; Toro, A.; Cano, F.; María Rodríguez, L.; Caro, E.; Martínez, J; Cornejo, W.; Mariano Gómez, L.; Luis Uribe, F.; Cárdenas, S.; Núñez V.; Díaz, A. Complications of Bothrops, Porthidium, and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital. Toxicon, 2002, 40(8), 1107-1114.
11. 2 by flavonoids: rationale for lead design. J. Comput. Aided. Mol. Des., 2007, 21(8), 473-83.
12. 2 inhibition and neutralization of free radicals by anti-oxidantsa new role as anti-inflammatory molecule. Curr. Topic. Med. Chem., 2007, 7(8), 765-777.
13. 2 inhibitors: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem., 2007, 7(8), 743-756.
14. Mandl, J.; Szarka, A.; Bánhegyi, G. Vitamin C: update on physiology and pharmacology. Br. J. Pharmacol., 2009, 157(7), 1097-1110.
15. Ohno, S.; Ohno, Y.; Suzuki, N.; Soma, G.; Inoue, M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res., 2009, 29(3), 809-815.
16. C.C.; Paul, A.S.; Carl hoseney, R,; Charles, W.D,; Yun, Y.L,; Donold, W.L. Synthesis of 6-fatty acid esters of L-ascorbic acid. J. Am. Oil. Chem. Soc., 1977, 54, 308-312.
17. 2 from Russell's viper (Vipera russellii) venom. Toxicon, 1989, 27, 229-237.
18. Patriarca, P.; Beckerdite, S.; Elsbach, P. Phospholipases and phospholipid turnover in Escherichia coli spheroplasts. Biochim. Biophys. Acta, 1972, 260, 593-600.
19. 2 activity in rats. J. Clin. Invest., 1993, 92, 1974-1980.
20. 2 with anti-inflammatory activity. Mol. Cell Biochem., 2005, 276(1-2), 219-225.
21. Yamakawa, M. M.; Hokama, N. Z. Fractionation of Sakishima habu (T. elegans) venom and lethal hemorrhagic and edema forming activity of the fractions. In: A. Ohsaka, K. Hayashi, Y. Sawai (ed), Animal, Plant and microbial toxins. 1976, Vol.1, Plenum press, New York, p.97.
22. 2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid. Toxicon, 1987, 25(5), 501-515.
23. Gutiérrez, J.M.; Arce, V.; Brenes, F.; Chaves, F. Changes in myofibrillar components after skeletal muscle necrosis induced by a myotoxin isolated from the venom of the snake Bothrops asper. Exp. Mol. Pathol., 1990, 52(1), 25-36.
24. Thomsen, R.; Christensen, M.H. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem., 2006, 49(11), 3315-3321.
25. Schuettelkopf, A.W.; van Aalten, D.M.F. PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica, 2004, D60, 1355-1363.
26. 2 from Daboia russelli pulchella at 2.4 A resolution. J. Mol. Biol., 2000, 296(4), 1117-26.
27. 2 inhibitors: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem., 2007, 7(8), 743-756.
28. 2 and alpha-tocopherol at 1.8 A resolution. J. Mol. Biol., 2002, 320(2), 215-222.
29. Lavrenov, S.N.; Preobrazhenskaya, M.N. L-ascorbic acid: properties and ways of modification. Phram. Chem. J., 2005, 39, 251-264.
30. 2 biochemistry. Cardiovasc. Drugs Ther., 2009, 23(1), 49-59.
31. 2 by minocycline and doxycycline. Biochem. Pharmacol., 1992, 44(6), 1165-1170.
32. 2 by lipocortins and calpactins. An effect of binding to substrate phospholipids. J. Biol. Chem., 1987, 262(4), 1698-1705.
33. 2 inhibition by ursolic acid: a potent anti-inflammatory molecule. Curr. Top. Med. Chem., 2007, 7(8), 801-809.
34. 2. Planta Med., 2009, 75(3), 211-215.
35. Uma, B.; Gowda, T.V. Molecular mechanism of lung haemorrhage induction by VRV-PL-VIIIa from Russell's viper (Vipera russelli) venom. Toxicon, 2000, 38(8), 1129.
36. 2 from Russell's viper (Vipera russelli) venom. Toxicon, 1989, 27(8), 875-885.
37. 2 by retinoids and flavonoids. Mechanism of action. Agents Actions, 1988, (3-4), 3 BS 94-400.
38. 2 enzymes. Biochem. J., 1996, 320 (Pt 1), 93-99.
39. Ranjbar, B.; Gill, P. Circular dichroism techniques: biomolecular and nanostructural analyses- a review. Chem. Biol. Drug Des., 2009,74(2), 101-120.
40. 2 from Vipera russelli venom with aristolochic acid: a circular dichroism study. Toxicon, 1987, 25(9), 939-946.
41. Lin, Y.H.; Huang, W.N.; Lee, S.C.; Wu, W.G. Heparin reduces the alpha-helical content of cobra basic phospholipase A(2) and promotes its complex formation. Int. J. Biol. Macromol., 2000, 27(2), 171-176.
42. 2-a structural review. Toxicon, 1996, 34(8), 827-841.
43. Berg, O.G.; Gelb, M.H.; Tsai, M.D.; Jain, M.K. Interfacial enzymology: the secreted phospholipase A(2)-paradigm. Chem. Rev., 2001, 101(9), 2613-2654.
44. 2 by polyhydroxy phenolic compounds. Eur. J. Med. Chem., 2009, 44(1), 312-321.
45. 2-inhibitor complexes. Indian J. Biochem. Biophys., 2008, 45(4), 256-262.
46. 2 from snake venoms: effects on catalytic and pharmacological properties. Toxicon, 2003, 42(8), 855-868.